These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16682709)

  • 61. Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
    Iyengar SS; Nair T; Sathyamurthy I; Hiremath JS; Jadhav U; Kumbla D; Jain RK; Srinivasan M; Sahoo PK; Chawla K; Katiyal VK
    Indian Heart J; 2009; 61(5):480-1. PubMed ID: 20635768
    [TBL] [Abstract][Full Text] [Related]  

  • 62. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
    Morrow DA; Antman EM; Fox KA; White HD; Giugliano R; Murphy SA; McCabe CH; Braunwald E;
    Eur Heart J; 2010 Sep; 31(17):2097-102. PubMed ID: 20400762
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial.
    Armstrong PW; Zheng Y; Westerhout CM; Rosell-Ortiz F; Sinnaeve P; Lambert Y; Lopes RD; Bluhmki E; Danays T; Van de Werf F;
    Am Heart J; 2015 Jun; 169(6):890-898.e1. PubMed ID: 26027628
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enoxaparin for the treatment of acute myocardial infarction with persistent ST-segment elevation.
    Rubboli A; Herzfeld I; Maresta A
    Minerva Cardioangiol; 2003 Oct; 51(5):463-70, 470-4. PubMed ID: 14551516
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
    Tanswell P; Modi N; Combs D; Danays T
    Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital.
    Ahmad A; Patel I; Asani H; Jagadeesan M; Parimalakrishnan S; Selvamuthukumaran S
    Indian J Pharmacol; 2015; 47(1):90-4. PubMed ID: 25821318
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
    Fox KA; Antman EM; Montalescot G; Agewall S; SomaRaju B; Verheugt FW; Lopez-Sendon J; Hod H; Murphy SA; Braunwald E
    J Am Coll Cardiol; 2007 Jun; 49(23):2249-55. PubMed ID: 17560289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety and efficacy of tenecteplase in acute myocardial infarction.
    Guerra DR; Karha J; Gibson CM
    Expert Opin Pharmacother; 2003 May; 4(5):791-8. PubMed ID: 12740001
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and safety of tenecteplase in Indian patients with st-segment elevation myocardial infarction.
    Sathyamurthy I; Srinivasan KN; Jayanthi K; Vaidiyanathan D; Prabhakar D; Ramachandran P
    Indian Heart J; 2008; 60(6):554-7. PubMed ID: 19276495
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy.
    Thomas D; Giugliano RP
    J Thromb Thrombolysis; 2009 Jan; 27(1):1-10. PubMed ID: 18931978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry.
    El-Rayes M; Schampaert E; Tardif JC; Eisenberg MJ; Afilalo M; Kouz S; Lauzon C; Harvey R; Nguyen M; Kouz R; Dery JP; Mansour S; Van Kieu AM; Rinfret S; Huynh T
    Can J Cardiol; 2010 Oct; 26(8):431-6. PubMed ID: 20931096
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
    Montalescot G; Zeymer U; Silvain J; Boulanger B; Cohen M; Goldstein P; Ecollan P; Combes X; Huber K; Pollack C; Bénezet JF; Stibbe O; Filippi E; Teiger E; Cayla G; Elhadad S; Adnet F; Chouihed T; Gallula S; Greffet A; Aout M; Collet JP; Vicaut E;
    Lancet; 2011 Aug; 378(9792):693-703. PubMed ID: 21856483
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study.
    Cantor WJ; Burnstein J; Choi R; Heffernan M; Dzavik V; Lazzam C; Duic M; Fitchett D; Tan M; Wawrzyniak J; Kassam S; Dhingra S; Morrison LJ; Langer A; Goodman SG
    Can J Cardiol; 2006 Nov; 22(13):1121-6. PubMed ID: 17102829
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
    Ruff CT; Wiviott SD; Morrow DA; Mohanavelu S; Murphy SA; Antman EM; Braunwald E;
    Am J Med; 2007 Nov; 120(11):993-8. PubMed ID: 17976428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
    Mahaffey KW; Cohen M; Garg J; Antman E; Kleiman NS; Goodman SG; Berdan LG; Reist CJ; Langer A; White HD; Aylward PE; Col JJ; Ferguson JJ; Califf RM;
    JAMA; 2005 Nov; 294(20):2594-600. PubMed ID: 16304073
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.
    Tatu-Chiţoiu G; Teodorescu C; Dan M; Căpraru P; Guran M; Istrătescu O; Tatu-Chiţoiu A; Bumbu A; Dorobanţu M
    Rom J Intern Med; 2003; 41(4):395-408. PubMed ID: 15526522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.